Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:11 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 380 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Antipsychotic Clear all

Conditions: Weight Loss, Diabetes Mellitus, Type 2, Psychotic Disorders
Interventions: Premier Lifestyle Intervention with DASH Diet; Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 3
States / cities: Portland, Oregon

Conditions: Schizophrenia
Interventions: Antipsychotic/Risperidone Consta; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 2
States / cities: Butner, North Carolina • Durham, North Carolina

Conditions: Mild Traumatic Brain Injury
Interventions: Quetiapine Fumarate, TAU; Drug
Lead sponsor: Foundation for Advancing Veterans' Health Research; Other
Eligibility: 18 Years to 65 Years
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Albuquerque, New Mexico • San Antonio, Texas

Conditions: Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions: ziprasidone; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Delirium, Epileptics, Neuroleptics
Interventions: Haloperidol, Chlorpromazine, Valproate, Placebo; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Schizophrenia Disorders
Interventions: Xanomeline and Trospium Chloride; Drug
Lead sponsor: Collaborative Neuroscience Research, LLC; Network
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 7
States / cities: Bellflower, California • Garden Grove, California • Riverside, California + 4 more

Conditions: Schizophrenia, Schizoaffective Disorder, Psychotic Disorder, Substance Abuse, Alcohol Abuse
Interventions: Quetiapine; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 4
States / cities: Augusta, Georgia • Lebanon, New Hampshire • Manchester, New Hampshire

Conditions: Weight, Body
Interventions: Risperidone, Aripiprazole; Drug
Lead sponsor: Duke University; Other
Eligibility: 3 Years to 18 Years
Enrollment: 509 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 37
States / cities: Dothan, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 32 more

Conditions: Bipolar I Disorder
Interventions: Lithium treatment in combination with a SGA (Second Generation Antipsychotic), Placebo/Adjunctive SGA treatment; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 12 Years to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Glen Oaks, New York

Conditions: Drug-induced Weight Gain
Interventions: RDX-002 + Olanzipine, Olanzapine; Drug
Lead sponsor: Response Pharmaceuticals; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Healthy
Interventions: Olanzapine; Drug
Lead sponsor: Dost Ongur; Other
Eligibility: 21 Years to 50 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Depression
Interventions: Risperidone and placebo comparator; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Schizophrenia, Bipolar Disorder
Interventions: Risperidone long acting injectable - New Starts, Risperidone long acting injectable - Continuous Users, Paliperidone Palmitate -New and Continuous Users, Other Antipsychotics - New Starts; Drug
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 1,066 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 34
States / cities: Bullhead City, Arizona • Colton, California • Imperial, California + 31 more

Conditions: Schizophrenia
Interventions: CT-155, Digital Control; Device
Lead sponsor: Click Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 54
States / cities: Chandler, Arizona • Phoenix, Arizona • Anaheim, California + 50 more

Conditions: Schizophrenia
Interventions: Placebo, bitopertin [RO4917838]; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 624 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 21
States / cities: Carson, California • Oceanside, California • San Diego, California + 17 more

Conditions: Behavioral and Psychiatric Symptoms of Dementia, Insomnia
Interventions: Recommendation to Deprescribe; Drug
Lead sponsor: Tabula Rasa HealthCare; Industry
Eligibility: 55 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Pennsauken, New Jersey

Conditions: Schizophrenia
Interventions: Not listed
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years to 55 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2021
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Schizophrenia
Interventions: Abilify MyCite®; Combination Product
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 277 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 68
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 55 more

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Risperidone, Olanzapine, Quetiapine, Aripiprazole; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 28
States / cities: Colton, California • Palo Alto, California • New Haven, Connecticut + 25 more

Conditions: Major Depressive Disorder
Interventions: Switching: Bupropion-SR, Augmenting: Antidepressant + Bupropion-SR, Augmenting: Antidepressant + Aripiprazole; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 1,522 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 35
States / cities: Tuscaloosa, Alabama • Phoenix, Arizona • Tucson, Arizona + 32 more

Conditions: Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions: Aripiprazole, Risperidone, Modafinil; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 40 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: San Francisco, California

Conditions: BiPolar
Interventions: ADASUVE®; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Atlanta, Georgia • Cincinnati, Ohio

Conditions: Schizophrenia
Interventions: Antipsychotic medication adherence intervention; Behavioral
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years to 70 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: No. Little Rock, Arkansas

Conditions: Childhood Schizophrenia, Psychotic Disorder, Schizophrenia
Interventions: Olanzapine, Clozapine; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 7 Years to 18 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Reducing Weight and Diabetes Risk in an Underserved Population (STRIDE)

Functional Brain Imaging and Employment in First-Episode Psychotic Patients Treated With Risperdal

Quetiapine to Reduce Post Concussive Syndrome After Mild Traumatic Brain Injury (mTBI)

Improving Diabetes Risk Factors in Persons With Schizophrenia or Bipolar Disorder by Switching to Ziprasidone

Managing Agitated Delirium With Neuroleptics and Anti-Epileptics as a Neuroleptic Sparing Strategy

An 8-week Open-label Study of an Accelerated and Slower Switching to Xanomeline/Trospium Following Atypical Antipsychotic Treatment in Participants With Schizophrenia

Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder

Long-term Antipsychotic Pediatric Safety Trial

Study of the Efficacy of Adjunctive Lithium Treatment for the Treatment of Psychotic Mania

Effect of RDX-002 on Postprandial Triglycerides in Subjects Treated With Olanzapine

The Effects of Antipsychotic Drugs on Brain Metabolism in Healthy Individuals

Risperidone and Suicidality in Major Depressive Disorder

Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations

Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of Schizophrenia

A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25309)

Implementation of a Pharmacist-Driven Antipsychotic Deprescribing Initiative in the PACE Setting: A Pilot Study

Treatment Response in Schizophrenia: Bridging Imaging and Postmortem Studies

A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®

Comparison of Antipsychotics for Metabolic Problems in Schizophrenia or Schizoaffective Disorder

VA Augmentation and Switching Treatments for Improving Depression Outcomes

Antipsychotic Effects on Brain Function in Schizophrenia

Study to Assess the Safety and Pharmacokinetics of ADASUVE® at Doses of 2.5, 5, or 10 mg in Children and Adolescents (10 Through 17 Years of Age) With Any Condition Warranting Chronic Use of an Antipsychotic Medication

Patient-Centered Medication Adherence Intervention for Schizophrenia

Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders